1 / 4

PO-67 M. Martinez-Rebollar et al.

PO-67 M. Martinez-Rebollar et al. Objective To identify factors associated with virological, immunological and clinical outcome in naïve patients who have initiate HAART from January 1997 to December 2006. Methods Retrospective cohort study

mercia
Download Presentation

PO-67 M. Martinez-Rebollar et al.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PO-67 M. Martinez-Rebollar et al. Objective To identify factors associated with virological, immunological and clinical outcome in naïve patients who have initiate HAART from January 1997 to December 2006. • Methods • Retrospective cohort study • Including all antiretroviral naïve patients who have initiate HAART from 1997 to 2006 in a tertiary hospital in Barcelona. • Evaluate by calendar year (1997-00, 2001-03 and 2004-06) and CD4 strata (<200, 201-350 and ≥350): • The demographic and clinical characteristics at the initiation of HAART • The composition of the antiretroviral regimen • CD4 response • Clinical outcome (development of new AIDS events and/or non-AIDS related mortality) using a multivariate analysis.

  2. PO-67 M. Martinez-Rebollar et al. 1.46 (1.06;2.02) Age 1 1 CD4 cell count 2.25 (1.27;4.01) 3.89 (2.32;6.52) 0.52 (0.32;0.86) Calendar year 0.71 (0.47;1.05) 1 6 Results: Adjusted Hazard Ratio (95%CI) of progression to aids and death Sex, age, VL at baseline, type of ARVc regimen, risk factor were also evaluated but not included in the final model

  3. PO-67 M. Martinez-Rebollar et al. Conclusions • In HAART era, the response to initial antiretroviral therapy in terms of CD4 rise, clinical outcome and survival has gradually and significantly improved. • But remain significantly worse among older patients and late presenters. • HAART should be initiated, at least, when CD4+ cell count drop < 350.

More Related